Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes - Abstract

BACKGROUND: Metformin has shown promise for cancer prevention.

Prior studies suggested that metformin might interact potential prostate cancer (PCa) prevention agents: finasteride and statins. This study assessed if concurrent use of statins or finasteride modified the long-term impact of metformin on PCa risk in men with type 2 diabetes (T2DM).

MATERIALS AND METHODS: The study cohort consisted of 71,999 men with T2DM seen in the Veteran Administration Health Care System, without prior cancer or liver diseases, nor prescription of thiazolidinediones or insulin between FY2003-FY2013. Cox proportional hazard analyses (adjusting for covariates and propensity scores of metformin use) were conducted to compare the hazard ratio (HR) of PCa associated with metformin use between statins or finasteride users and none users.

RESULTS: Mean follow-up was 6.4±2.8 years; 5.2% (N= 3,756) of the cohort subsequently received a PCa diagnosis. Both statins and finasteride significantly modified the impact of metformin on PCa incidence (p-value< 0.001): HR's of PCa associated with metformin use were 0.89 (p-value=0.02) among non-statin/non-finasteride users, 0.73 (p-value< 0.001) among statin users, and 1.42 (p-value< 0.001) among finasteride users.

CONCLUSION: Metformin was associated with reduced PCa risk in men with T2DM. This impact was enhanced by statins but reversed by finasteride. Metformin, statins, and finasteride are potential PCa prevention agents. The interaction of these drugs on PCa risk needs further confirmation in other cohorts. Our finding of differential impacts of metformin, statins, and finasteride (alone or in combination) on PCa risk is informative for treatment management in men at risk for PCa and T2DM.

Written by:
Chen-Pin W, Javier H, Lorenzo C, Downs JR, Thompson IM, Pollock B, Lehman D.   Are you the author?
Department of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, USA; Department of Urology, University of Texas Health Science Center San Antonio, USA; Department of Medicine; University of Texas Health Science Center San Antonio, USA.

Reference: Ann Transl Med Epidemiol. 2014;1(1). pii: 1004.

 
PubMed Abstract
PMID: 25621309

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe